Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Treatment

Editorial Comment: Fifty per cent of all HF patients involves Diastolic Heart Failure or HF with conserved ventricular function. This study aimed at evaluating the efficacy and safety of 25mg spironolactone after a year of therapy. Results showed improved diastolic function, induced structural inverse remodelling, reduced neuroendocrine activation and reduced blood pressure (effects on cardiac structure and function remained significant after adjusting for blood pressure changes). Authors concluded that, in addition to safety, this drug is an effective alternative to treat these patients

aldoHF-slides
B. Pieske
2012-08-25

Original title: Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure

More articles by this author

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25

DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.

 DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.  Read articleJames K. Min2012-08-25

PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .

Editorial Comment: This Phase II study included 149 patients following these criteria: NYHA II-IV heart failure, +40 yr, LVEF ≥ 45% NT-proBNP> 400 pg/ml....

ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.

Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...